SAN
DIEGO, Nov. 2, 2022 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a company developing medical
therapeutics to treat cancer and life-threatening infectious
disease, today announced that it will issue financial results for
its second quarter ended September 30,
2022, at 4:15 p.m. EST on Monday,
November 14, 2022.
Management will host a conference call on Monday, November 14, 2022 at 4:30 p.m. EST to review financial results and
recent corporate developments. Following management's formal
remarks, there will be a question and answer session.
Interested parties can register for the conference by navigating
to https://dpregister.com/sreg/10172901/f4fe08e0d7. Please
note that registered participants will receive their dial in number
upon registration.
Interested parties without internet access or unable to
pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE):
1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN:
1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference
call.
A replay of the call will be available approximately one hour
after the end of the call through December
14, 2022. The replay can be accessed via Aethlon Medical's
website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088
(international) or Canada toll
free at 1-855-669-9658. The replay conference ID number is
2753791.
About Aethlon and the
Hemopurifier®
Aethlon Medical is a medical therapeutic company developing the
Hemopurifier, a therapeutic blood filtration system indicated for
infectious diseases and cancer. In human studies, the Hemopurifier
has demonstrated the removal of life-threatening viruses and
harmful exosomes from blood utilizing a proprietary lectin-based
technology. This action has potential applications in cancer, where
exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA)
designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease. Under an
Investigational Device Exemption (IDE) application, the FDA
approved a single site, open-label Early Feasibility Study (EFS) to
evaluate the Hemopurifier for reducing cancer-associated exosomes
prior to the administration of standard-of-care pembrolizumab
(KEYTRUDA®) in patients with recurrent and/or metastatic squamous
cell carcinoma of the head and neck.
The Hemopurifier also holds an FDA Breakthrough Device
designation and an open IDE application related to the treatment of
life-threatening viruses that are not addressed with approved
therapies. A recent amendment to the IDE enabled Aethlon to
implement a new EFS protocol to treat up to 40 COVID-19 patients at
up to 20 clinical sites in the U.S. In two case studies of
patients treated under Emergency Use (EU), the Hemopurifier
demonstrated binding of SARS-CoV-2 spike protein and removal of
SARS-CoV-2 virus from the circulation of a human patient.
Additional information can be found
at www.AethlonMedical.com.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-second-quarter-financial-results-and-host-conference-call-on-november-14-2022-301666682.html
SOURCE Aethlon Medical, Inc.